Ayala Hernández J R, de la Huerta Sánchez R, Morales Canfield F, Fernández Orozco A
Departamento de Radioterapia, Hospital de Oncología, CMN, IMSS.
Ginecol Obstet Mex. 1991 Jul;59:238-42.
55 patients with stage III carcinoma of the uterine cervix were entered into a prospective randomized study to evaluate the possible radiation-potentiating properties of bleomycin. Group A received classical radiation treatment with telecobalt-therapy 50 Gy/25 fractions plus 32 Gy/4 fractions (Cathetron). The other two groups received 15 mg of bleomycin by continue infusion two time of week during 5 week, groups B before, and group C after, irradiation. The morbidity was minimal. The initial response was complete in 49 cases and partial in 6 cases. At 2 years there were 26 recurrences, 22 (88.8%), locoregional recurrences and 4 distant metastasis, 3 in the group of bleomycin treatment. The probability of actuarial survival was 62.1%, 30.1% and 35.6% respectively to groups A, B and C. Addition of bleomycin to radiotherapy failed to increase the recurrence-free survival.
55例III期宫颈癌患者进入一项前瞻性随机研究，以评估博来霉素可能的放射增敏特性。A组接受传统放疗，采用远距离钴治疗，50 Gy分25次给予，外加32 Gy分4次给予（卡特龙）。另外两组在5周内每周两次持续输注15 mg博来霉素，B组在放疗前，C组在放疗后。发病率很低。初始反应完全缓解49例，部分缓解6例。2年时有26例复发，22例（88.8%）为局部区域复发，4例为远处转移，其中3例在博来霉素治疗组。A、B、C三组的精算生存率分别为62.1%、30.1%和35.6%。放疗中添加博来霉素未能提高无复发生存率。
